Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: estatemakr who wrote (312)	10/1/2007 4:35:00 PM
From: Keith Feral	Read Replies (1) \| Respond to of 418

Who knows, I don't blame people for trying in biotech. All the due diligence comes down to guesswork. I'm pretty comfotable with the concepts behind ANX technology, and I hope it works out in phase 3 bolus treatment. The infusional delivery didn't work as well as the bolus procedures, and the value of the company has been destroyed. The product works better than leucovorin, there is no doubt in my mind. I thought the company had everything planned out pretty well, but these unexplained improvement in side effects from the Leucovorin subgroup are mind boggling.